Rivastigmine for Alzheimer's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Birks, Jacqueline ^a   Evans, John Grimley ^b   Iakovidou, Vasso ^c   Tsolaki, Magda ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Aristotle University of Thessaloniki ^*

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

*Phenylcarbamates; Alzheimer disease *drug therapy ; Carbamates administration dosage; *therapeutic use ; Cholinesterase inhibitors administration dosage; *therapeutic use ; Cognition disorders drug therapy ; Humans; Randomized controlled trials as topic; Severity of illness index

Indexed keywords

PLACEBO; RIVASTIGMINE;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; ASTHENIA; BRAIN REGION; CHOLINERGIC TRANSMISSION; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; DAILY LIFE ACTIVITY; DATA ANALYSIS; DATA BASE; DATA EXTRACTION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; FUNCTIONAL ASSESSMENT; HUMAN; MEDLINE; META ANALYSIS; NAUSEA; PSYCINFO; QUALITY OF LIFE; RATING SCALE; REVIEW; SCORING SYSTEM; SIDE EFFECT; SYNCOPE; SYSTEMATIC REVIEW; VOMITING; WEIGHT REDUCTION;

EID: 70349119559     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001191.pub2     Document Type: Review

References (174)

1. Agid Y, Dubois B on behalf of the International Rivastigmine Investigators, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research 1998;59(12):837-845.
2. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview. J Drug Dev Clin Pract 1996;8(2):109-116. (Pubitemid 26320765)
3. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview. J Drug Dev Clin Pract 1996;8(2):109-116. (Pubitemid 26320765)
4. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon® ). Eur J Neur 1999;6:423-429. (Pubitemid 29371138)
5. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996;8(2):109-116 (Pubitemid 26320765)
6. Cutler N, Sramek J, Anand R. Safety and Tolerance of ENA 713 in Alzheimer's Disease (AD). Proceedings of the 8th European College of Neuropsychopharmacology Congress (ECNP); 1995 Sep 30-Oct 4, Venice. 1995. [MEDLINE: SR-HANDSRCH]
7. Cutler NR, Sramek JJ, Anand R. Safety and tolerance of ENA 713 in patients with alzheimer's disease. Biological Psychiatry 1995;37(9): 643.
8. Sramek J, Anand R, Wardle T, Irwin P, Hartman R, Cutler N. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996;58(15):1201-1207 (Pubitemid 26093988)
9. Anand R, Hartman R, Graham S. Effects of Alzheimer's disease severity on activities of daily living with long-term rivastigmine treatment. Journal of the American Geriatrics Society 2001;49(4):S151.
10. Anand R,Messina J, Veach J, Hartman R. Effects of Rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden. 2000:199.
11. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry 2004;19(3):243-249. (Pubitemid 38401128)
12. Erkinjuntti T, Skoog I, Lane R, Andrews C. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice 2003;57(9):756-760. (Pubitemid 37540597)
13. Erkinjuntti T, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice 2002;56(10):791-796. (Pubitemid 36104547)
14. Farlow M, Anand R, Messina J, Hartman R. Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co-existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden. 2000:206.
15. Farlow M, Messina J, Anand R, Hartman R, Veach J. Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. In: Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden. 2000. 2000:172.
16. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Archives of Neurology 2003;60: 843-848. (Pubitemid 36705972)
17. Hebert M. [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale 1999;28(32):1757-1758
18. Kumar V, Messina J, Hartman R, Anand R. Long-term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden. 2000:215.
19. Lindesay J. An open label one-year extension of SDZ-ENA-713 studies B303, B304 and B305 to prospectively evaluate long-term safety, tolerability and efficacy of SDZ-ENA-713 in out-patients with probable Alzheimer's disease. National Research Register 2000.
20. Roesler M, Retz W, Retz Junginger P, Dennler HJ. Effect of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural-Neurology 1998;11(4):211-216 (Pubitemid 30623645)
21. Rösler M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. British Medical Journal 2001; Vol.322, issue 7300:1456.
22. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318(7184):633-638.
23. Rösler M, Dennler H, Retz W, Gastpar W. A double-blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry 1997;30:212. [MEDLINE: SR-HANDSRCH]
24. Rösler M, Retz W, Retz Junginger P, Dennler HJ. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural-Neurology 1998;11(4):211-216 (Pubitemid 30623645)
25. Vincent S, Andrews C, Lane R. Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva. 2002:253.
26. Wilkinson DG. Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club 1999;131(2):34. [MEDLINE: Cinahl]
27. Feldman HH, Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry 2007;78 (10):1056-1063.
28. Lindesay J. An open label one-year extension of SDZ-ENA-713 studies B303, B304 and B305 to prospectively evaluate long-term safety, tolerability and efficacy of SDZ-ENA-713 in out-patients with probable Alzheimer's disease. National Research Register 2000.
29. Novartis. No title. Unpublished. Data provided by Novartis No year.
30. Novartis Pharmaceuticals. ADENA Programme. Unpublished Data 1998.
31. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry 2004;19(3):243-249. (Pubitemid 38401128)
32. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Archives of Neurology 2003;60: 843-848. (Pubitemid 36705972)
33. Novartis. No title. Unpublished. Data provided by Novartis No year.
34. Novartis Pharmaceuticals. ADENA Programme. Unpublished Data 1998.
35. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry 2004;19(3):243-249. (Pubitemid 38401128)
36. Corey-Bloom J, Anand R and Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Ger Psychopharmacology 1998;1:55-65. (Pubitemid 28323228)
37. Doraiswamy M. The effects of rivastigmine on the alzheimer's disease assessment scale-cognitive subscale items scores of patients with alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American geriatrics society and the American federation for aging research; 2000 May 17-21, Nashville. 2000:173.
38. Doraiswamy PM, Anand R, Hartman R. Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately-severe to severe AD. Clinical Neuropschological Assessment 2000;1(6):12.
39. Doraiswamy PM, Anand R, Hartman R. Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment 2000;1(6):14.
40. Farlow M, Hake A, Messina J, Veach J, Anand R. The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology 2000; Vol.54, issue Suppl 3:A469.
41. Farlow M, Messina J, Anand R. Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville. 2000:172.
42. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Archives of Neurology 2003;60: 843-848. (Pubitemid 36705972)
43. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R. Response of patients withAlzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology 2001;58(3):417-422 (Pubitemid 32217458)
44. Ferris S. Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver. 1999:77.
45. Krishnan KR, Dorasiswamy PM, Messina J, Veach J, ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the AmericanGeriatrics Society 1999; 47:S3.
46. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology 2000; 7(2):159-169 (Pubitemid 32260563)
47. Veach KR, Doraiswamy PM. Rivastigmine slows stage-specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999May 15-20, Washington DC. 1999. [MEDLINE: SR-HANDSRCH]
48. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'brien J, Everratt A, Sadler S,Maddison C, Lee L, Bannister C, Elvish R, Jacoby R. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005;330:874.
49. Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology 2007;69(4 Suppl 1):S23-S28. (Pubitemid 47205656)
50. Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007;7(11):1457-1463. (Pubitemid 350106826)
51. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease- rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry 2007;22(5):456-467. (Pubitemid 46831690)
52. Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer's disease. Neurology 2007;69(4 Suppl 1):S14-S22. (Pubitemid 47205655)
53. Winblad B, Kawata AK, Beusterien KM, THomas SK, Wimo A, Lane R, Fillit H, Blesa R. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry 2007;22(5):485-491. (Pubitemid 46831693)
54. Karaman Y, Erdogan F, Koseoglu E, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and geriatric cognitive disorders 2005;19(1):51-56 (Pubitemid 39664190)
55. Lopez-Pousa S. Pilot, multicenter, randomized, double-blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non-cognitive symptoms in patients with moderate-to-severe Alzheimer's disease. IFPMA Register 2005.
56. Mowla A, Mosavinasab M, Haghshenas H, Haghighi AB. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. Journal of Clinical Psychopharmacology 2007;27 (5):484-487. (Pubitemid 47415047)
57. Tai CT, Liu CK, Sung SM, Pai MC, Hsu CY. The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26-week study in Taiwan. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S356. [MEDLINE: SR-HANDSRCH]
58. Almkvist O, Darreh Shori T, Stefanova E, Spiegel R, Nordberg A. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.. European journal of neurology 2004;11(4): 253-261 (Pubitemid 38491099)
59. Auriacombe S, Pere JJ. No donepezil discontinuation effect in patients with alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment. Current Medical Research and Opinion 2003;19(8):715-717. (Pubitemid 37466141)
60. Auriacombe S, Pere JJ, Loria Kanza, Vellas B. Efficacy and safety of rivastigmine in patients with alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical Research and Opinion 2002;18(3):129-138 (Pubitemid 34665750)
61. Bilikiewicz A, Opala G, Podemski R, Puzynski S, Lapin J, Soltys K, Ochudlo S, Barcikowska M, Pfeffer A, Bilinska M, Paradowski B, Parnowski T, Gabryelewicz T. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.. Medical science monitor international medical journal of experimental and clinical research 2002;8(2):PI9-15. (Pubitemid 34218470)
62. Brassen S, Adler G. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.. Pharmacopsychiatry 2003;36(6): 304-308 (Pubitemid 38085149)
63. Caffarra P, Vezzadini G, Copelli S, Dieci F, Messa G, Nonis E, Venneri A. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors. Acta Biomedica 2007;78(1):16-21. (Pubitemid 47075718)
64. Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D. Longterm effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Current medical research and opinion 2004;20(10):1605-1612 (Pubitemid 39457548)
65. Cummings J, Anand R, Koumaras, et al. Abstract S79.002. Neurology 2000;54:A468.
66. Cutler NR, Polinsky R, Sramek JJ, Enz A, Jhee S, Mancione L, Hourani J, Zolnouni P. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998;97:244-250. (Pubitemid 28172559)
67. Cutler NR, Hossain M, McDonald C, Pommier F, Sedek G, Jhee SS, Sramek JJ. Pharmacokinetics of rivastigmine and its metabolite in patients with Alzheimer's disease. Biological Psychiatry 2000;47 (Suppl 1):S161.
68. Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, Cutler NR. Non-blinded bioavailability study of oral and intravenous rivastigmine. Clinical Pharmacokinetics 2002;41(3):225-234
69. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. International Journal of Clinical Practice 2006;60(1):110-118. (Pubitemid 43732587)
70. Doraiswamy M. Early intervention with a cholinesterase inhibitor produces long-term beneficial effects inmoderately severe ad patients. Proceedings of theWorld Alzheimer Congress; 2000 Jul 9-13,Washington. 2000a.
71. Edwards K, Goddman W, Anand R, Koumars B, Hartman R. Effect of Alzheimer's disease severity on psychotropic drug use and behavior in nursing home patients trated with rivastigmine. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:296.
72. Anon. Double-blind trial will compare two anti-alzheimer's drugs. Journal of Dementia Care 2001c; Vol.9, issue 5:6.
73. Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenetic Genomics 2006;16(11):771-774 (Pubitemid 44632290)
74. Bullock R, Bergman H, Touchon J, Gasmbina G, He Y, Nagel J, Lane R. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. CurrentMedical Opinion 2006;22 (3):483-494
75. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate tomoderately severe Alzheimer's disease over a 2-year period. Current Medical Research and Opinions 2005;21(8):1317-1327. (Pubitemid 41140736)
76. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate tomoderately- severeAlzheimer's disease over a 2-year period. Current Medical Research and Opinion 2005;21(8):1317-1328 (Pubitemid 41140736)
77. Bullock RA, Gambina G, Lane R, Nagel J. Rationale and design of EXCEED, a 24-month, double-blind study comparing rivastigmine and donepezil. Annals of Neurology 2002;52(3, suppl 1):30.
78. Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Current Medical Research Opinion 2006;22(1):49-59. (Pubitemid 43106907)
79. Frankfort SV, Appels BA de Boer A, Tulner LR, van Campen JPCM, Koks CHW, Beijnen JH, Schmand BA. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiology and Drug Safety 2007;16(5):545-551.
80. Fuschillo C, La Pia S, Campana F, Pinto A, De Simone L. Cognitive deficits in alzheimer's disease: treatment with acetylcholinesterase inhibitor agents. Archives of Gerontology and Geriatrics 2001;33(Suppl 1):151-158 (Pubitemid 32727479)
81. Holmes C, Wilkinson D, Dean C, Clare C, El-Okl M, Hensford C, Moghul S. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. International Journal of Geriatric Psychiatry 2007; 22(4):380-381. (Pubitemid 46680850)
82. Feldman H, Scheltens E, Hermann N, Ferris S, Mesenbrink P, Satlin A, Mancione L. Behavioral symptoms in mild cognitive impairment findings from the inddex study. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:522.
83. Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, Tekin S, Lane R, Ferris S. Behavioural symptoms in mild cognitive impairment. Neurology 2004;62:1199-1201. (Pubitemid 38456520)
84. Ferris S. Investigation into Delay to Diagnosis of Alzheimer's Disease with Exelon (InDDEx). Alzheimer's Disease Education and Referral Center (ADEAR) 1999a. [MEDLINE: www.alzheimers.org]
85. Ferris S, Feldman P, Mesenbrink P, Mancione L, Satlin A. Mild Cognitive impairment and Alzheimer's disease are these distinct study populations clinical trials. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002: 570.
86. Rossor MN. A prospective randomised mc double blind placebo controlled parallel group study of the effect of Exelon on the time to clinical diagnosis of Alzheimer's disease in subjects with mild cognitive impairment. Current Controlled Trials 2001.
87. Rossor MN. Investigation into delay to diagnosis of Alzheimer's Disease with Exelon (InDDEx). Current Controlled Trials 2000.
88. Sharma T. A prospective, randomized, multi-centre, double-blind, placebo-controlled, parallel-group study of the effect of Exelon on the time to clinical diagnosis of Alzheimer's disease in subjects with mild cognitive impairment. National Research Register 2000 2000.
89. Sharma T. Investigating the neural correlates of cognitive enhancement with rivastigmine (Exelon (C)) using functional magnetic resonance imaging in people with mild Alzheimer's disease. National Research Register 2001.
90. Sharma T. Structural and functional MRI correlates of memory disorder in people with mild cognitive impairments or Alzheimer's disease. National Research Register 2003.
91. Kim SY. A 24 week trial investigating the safety tolerability and efficacy of rivastigmine in mild to moderately severe Alzheimer's disease patients in Korea. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:360.
92. Malsch U, Dennler H J. [Treatment of Alzheimer's disease: Tolerability of rivastigmine during the initial period]. Psycho 2001;27(6): 337-342
93. McMillan H. Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks [letter]. International Journal of Geriatric Psychiatry 1999; Vol.14, issue 12:1078-1079 (Pubitemid 30066045)
94. Novartis Pharmaceuticals Corporation. An Open-Label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease. ClinicalTrials.gov 2005.
95. Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. International Journal of Neuropsychopharmacology 2001;4(3):223-230 (Pubitemid 34101518)
96. Potkin SG, Wu JC, Messina J, Fleming K, Keator D, Bunney WE, An R. Neuroimaging techniques and applications. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20, Washington DC. 1999. [MEDLINE: SR-HANDSRCH]
97. Riepe MW, Adler G, Ibach B,Weinkauf B, Tracik F. Adding Memantine to Therapy with Rivastigmine in Patients with Mild To Moderate Alzheimer's Disease: Results of a 12-Week Pilot Study. 57th Annual Meeting of the American Academy of neurology, Miami Beach, April 2005. 2005, issue P06.081.
98. Rozzini L, Bargnani C, Bosio A, Chia F, Franzani S, Leonardi R, et al. Acetylcholinesterase inhibitors are effective in real world patients with mild tomoderate Alzheimer disease evidence froma large population treated with rivastigmine or donepezil. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:329.
99. Rozzini L, Bargnani C, Bosio A, Chia F, Franzoni S, Leonardi R, Ranzenigo A, Rozzini R, Saviotti FM, Turla M, Trabucchi M, Vicini B, Borroni B, Padovani A. Comparison of efficacy and safety of rivastigmine and donepezil in patients with mild to moderate alzheimer disease: results from a multicentre randomised trial.. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva. 2002:240.
100. Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria.. International Clinical Psychopharmacology 2002;17(2):81-85 (Pubitemid 34169651)
101. Shanks MF, Venneri A, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD. Cerebral blood flow and cognition enhanced by rivastigmine in a controlled study of alzheimer's disease. Alzheimer's Disease International, 17th International Conference, Christchurch, New Zealand, 25-27 October 2001. 2001:37.
102. Shua-Haim J, Smith J, Potel S. A head to study of donepezil aricept rivastigmine exelon and galantamine reminyl for the treatment of Alzheimer's disease safety tolerability clinical and caregiver impression after 4-5 months of treatment: a prospective study. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:286.
103. Shua-Haim J, Smith J, Amin S, Shua-Haim V. Comparison of combination therapy with rivastigmine exelon and donepezil aricept versus rivastigmine alone for treatment of Alzheimer's disease safety tolerability and clinical experience after one year of treatment a cross section study. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:292.
104. Shua-Haim JR, Smith JM, Amin S. Slow dose escalation of rivastigmine (exelon ® ) treatment of agitation in patients with alzheimer disease: an eight month prospective study. The International Symposiumon advances in Alzheimer therapy, 2002, Geneva. 2002:242.
105. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. International Journal of Clinical Practice 2005;59 (4):473-477 (Pubitemid 40467894)
106. Sobow T. Cholinesterase inhibitors in the real world: donepezil vs rivastigmine tolerability study. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva. 2002:244.
107. Stefanova E, Blennow K, Darreh-Shori T, Hellstrom-Lindhal E, Wall A, Almkvist O, Langstrom B, Nordberg A. Evaluation of cerebral glucose metabolism, CSF-TAU and CSF-A342 after long-term rivastigmine and tacrine treatments in alzheimer disease patients. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva. 2002:246.
108. Thomas A, Iacono D, Bonanni L, D' Andreamatteo G, Onofrj M. Donepezil, rivastigmine,and vitamin E in Alzheimer disease: A combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clinical Neuropharmacology 2001;24(1):31-42. (Pubitemid 32176479)
109. Tsolaki M, Gerothanassis D, Aristotle CP. Efficacy and safety of cholinesterase inhibitors a longitudinal comparative study between donepezil and rivastigmine. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:2038.
110. Venneri A, Shanks MF. Charting patterns of progression in treated and untreated patients with alzheimer's disease using spect. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:474.
111. Wang Y, Chen Q, Zhang Z, et al. The treatment by using rivastigmine for patients with alzheimer disease: results of a multicenter, randomized, open-labeled, controlled clinical trial. Chinese Journal of Neurology 2001;34(4):210-213 (Pubitemid 33086352)
112. Wang QH, Zhang ZX, Xu XH. [Efficacy of rivastigmine in treating mild to severe alzheimer's disease with different hachinski ischemia index]. Chinese Journal of Neurology 2003;36(1):44-47
113. Weiser M, Davidson M, Rotmensch H, Korczyn A, Hartman R, Cicin-Sain A, Anand R. A pilot randomised open label trial assessing safety and pharmacokinetic parameters of co administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:633.
114. Weiser M, Rotmensch HH, Korczyn AD, Hartman R, Cicin Sain A, Anand R, Rivastigmine Risperidone Study Group. A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.. International journal of geriatric psychiatry 2002;17(4):343-346 (Pubitemid 34467093)
115. Werber EA, Klein C, Rabey MJ. Evaluation of cholinergic treatment in demented by p300 evoked related potentials. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden. 2002:442.
116. Bullock R, Passmore F, Potocnik F, Hock C. The tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: a 12-week, multinational, comparative study. Journal of the American Geriatrics Society 2001;49(4):S19.
117. Potocnik FC, Smith R, Passmore P, Hock C, Wilkinson D, Maud CM, Hopker S. Tolerability, ease of use, and efficacy of donepezil and rivastigmine in alzheimer's disease patients. Proceedings of the AnnualMeeting of the American Psychiatric Association; 2001 May 5-10; New Orleans. 2001.
118. Wilkinson D, Passmore P, Potocnik F, Maud C, Hock C. Donepezil compared to rivastigmine in Alzheimer's disease: similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco. 2001.
119. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FCV, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. International Journal of Clinical Practice 2002;56(6):441-446. (Pubitemid 34855303)
120. Anand R, Messina J, Koumaras B, Hartman R. Reducing behavioural and functional disturbances in Alzheimer's disease: focus on rivastigmine. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, Stockholm. 2000:30.
121. Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002;42(5):558-568
122. Chiu MJ. A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease. ClinicalTrials.gov 2005.
123. Hodges JR. A randomised double blind placebo controlled multicentre study to assess the maximum tolerated dose and the efficacy of SDA ENA 713 in patients with Alzheimer 's disease.. Current Controlled Trials 2001.
124. Hodges JR. Prospective randomised multi-cente double blind, parallel groups, placebo controlled study to evaluate the efficacy and safety of individual highest well tolerated doses (range 2-12 mg/day) of SDZ ENA 713 given bd or tid in patients withmild tom. Current Controlled Trials 2001.
125. Hodges JR. Symptomatic efficacy and tolerability of SDZ ENA 713 in patients with mild to moderate dementia of the Alzheimer's type. Current Controlled Trials 2000c. [MEDLINE: http://www.doh.gov.uk/nrr.htm]
126. Holmes C. The effects of rivastigmine on non-cognitive symptoms in patients with severe Alzheimer's disease. National Research Register 2004a.
127. Bullock R. Making Evidence-based Decisions Using Alzheimer Therapy (MEDUSA Therapy). ISRCTN Register //http://www.controlled-trials.com/mrct 2005.
128. Memory Disorders Study Unit. Prospective, randomised, multicentre, double-blind, parallel-groups, placebo-controlled study to evaluate the efficacy and safety of individual highest well-tolerated doses (range 2-12 mg/day) of SDZ ENA 713 given bid or tid in patients with mild to moderate probable Alzheimer's Disease. South Australian Network For Research On Ageing (SANRA) 2000b.
129. Benton AL. Revised visual retention test. 4th Edition. San Antonio, Texas: The Psychological Association, 1974.
130. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [Art. No.: CD001190. DOI: 10.1002/14651858.CD001190] (Pubitemid 46841367)
131. Birks J. The evidence for the efficacy of cholinesterase inhibitors in the treatment of Alzheimer's disease is convincing. International Psychogeriatrics 2008;20(2):279-286.
132. Brunner C, Spiegel R. Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie [Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie]. Zeitschr für Psychologie 1990;XIX(3):211-219
133. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry 2004;19(3):243-249. (Pubitemid 38401128)
134. Chalmers TC, Celano P, Sacks HS, Smith H, Jr. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine 1983;309:1358-1361 (Pubitemid 14246558)
135. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: a systematic review. International Journal of Technology Assessment in Health Care 2002;18(3): 497-507.
136. Cohen-Mansfield J. Assessment of disruptive behaviour/agitation in the elderly: function, methods and difficulties. Journal of Geriatric Psychiatry Neurology 1995;8:52-60.
137. Cummings JL, Mega M, Gray K, Rosenburg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308-2313. (Pubitemid 24382728)
138. DeJong R, Osterlund OW, Roy GW. Measurement of Quality-of -Life changes in patients with Alzheimer's Disease. Clinical Therapeutics 1989;11(4):545-554. (Pubitemid 19202105)
139. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Press, 1994.
140. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Archives of neurology 2003a;60(6): 843-848 (Pubitemid 36705972)
141. Fillit H, Hill J. The economic benefits of acetylcholinesterase inhibitors for patients with alzheimer disease and associated dementias. Alzheimer Disease and Associated Disorders 2004;18(Suppl 1): S24-S29. (Pubitemid 38737790)
142. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-198.
143. Fuld PA. The Fuld object memory evaluation. Chicago: Steeling Instrument Co., 1981.
144. Galasko D, Schmitt FA, Sano M, et al.An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:33-39.
145. Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. International Journal of Geriatric Psychiatry 2000;15:242-247 (Pubitemid 30179175)
146. Grossberg GT. Cholinesterase inhibitors for the treatment of alzheimer's disease: getting on and staying on. Current Therapeutic Research Clinical and Experimental 2003;64(4):216-235 (Pubitemid 36692841)
147. Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in alzheimer disease: efficacy over two years. American Journal of Geriatric Psychiatry 2004;12(4):420-431. (Pubitemid 38878862)
148. Grossberg George, Irwin Peter, Satlin Andrew, Mesenbrink Peter, Spiegel Rene. Erratum. American Journal of Geriatric Psychiatry 2004;12(6):679.
149. Guy W, (ed). .,, 1976. ECDEU Assessment manual for psychopharmacology. Rockville: National Institute of Mental Health, 1976.
150. Hauber AB, Gnanasakthy A, Mauskopf JA. savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clinical Therapeutics 2000;22(4): 439-451 (Pubitemid 30304795)
151. Declaration of Helsinki. http://www.faseb.org/arvo/helsinki.htm.
152. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000;20: 1-12. (Pubitemid 30036098)
153. Kaufer D, Quarg P, Spiegel R. Consistent long-term efficacy of rivastigmine in mild, moderate and moderately severe Alzheimer's disease. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004. 2004.
154. Kaufer D, Quarg P SR, UNC School of Medicine, Chapel Hill, NC, USA. Consistent Long-term Efficacy of Rivastigmine in Mild, Moderate and Moderately Severe Alzheimer's Disease. NeuroBiology of Aging 2004;25(S2):101.
155. Kennedy JS, Polinsky RJ, Johnson B, Loosen P, Enz A, Laplanche R, Schmidt D, Mancione LC, Parris WC, Ebert MH. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. Journal of Clinical Psychopharmacology 1999;19:513-521
156. Marin D, Amaya K, Casciano R, Puder KL, Casciano J, Chang S, Snyder EH, Cheng I, Cuccia AJ. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.. International Psychogeriatrics IPA 2003;15(4):385-398 (Pubitemid 38186257)
157. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
158. Novartis Pharmaceutical (UK) Limited. EXELON (rivastigmine) Beyond cognition: prolonging functional ability. Product monograph. EXELON (rivastigmine) Beyond cognition: prolonging functional ability. Product monograph. Frimley, 1998.
159. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery: a neurological test for severely demented patients. Archives of Neurology 1994;51:41-45. (Pubitemid 24020169)
160. Polinsky RJ. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clinical Therapeutics 1998;20(4):634-646.
161. Reisberg B, Ferris SH, De Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. American Journal of Psychiatry 1982;139:1136-1139. (Pubitemid 12051593)
162. Reisberg B, Ferris SH. CIBIC-plus interview guide. Unknown: Unknown, 1994.
163. Reitan RM. The validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills 1958;8:271-276.
164. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of alzheimer disease. American Journal of Geriatric Psychiatry 2004;12(4):358-369 (Pubitemid 38878856)
165. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984;41:356-364.
166. Saxton J, McGonigle-Gibson K, Swihart A, Miller M, Boller F. Assessment of severely impaired patients: description and validation of a new neuropsychological test battery. Psychological Assessment 1990; 2:298-303.
167. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11(Suppl 2):S22-S32.
168. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1998;1:S26-S34. (Pubitemid 28563272)
169. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408-412.
170. Spencer CM,Noble S. Rivastigmine A review of its use in Alzheimer's disease. Drugs & Aging 1998;13(5):391-411. (Pubitemid 28523796)
171. Watson YI, Arfken CL, Birge SJ. Clock completion: an objective screening test for dementia. Journal of the American Geriatric Society 1993;41:1235-1240.
172. Wechsler D. Wechsler Memory Scale-Revised (WMS-R). San Antonio: Psychological Corporation Harcourt Brace Jovanovich Inc, 1987.
173. Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. Clinical therapeutics 2003;25(6): 1634-1653 (Pubitemid 36801939)
174. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001191]